Kornimate/medical-research-clean huggingface dataset:
nitric oxide in myocardial infarction size

Conditions: Acute Myocardial Infarction; ST Elevation MI; STEMI

Summary: the purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (mi) size at 48-72 hours in patients presenting with an st segment elevation mi (stemi) who undergo successful percutaneous coronary intervention.

the purpose of the trial is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (mi) size as a fraction of left ventricular (lv) size at 48-72 hours in patients presenting with an st segment elevation mi who undergo successful percutaneous coronary intervention (pci). the primary endpoint for this study will be myocardial infarction size as a fraction of left ventricular size at 48-72 hours as measured by contrast-enhanced cardiac mri.

Eligibility criteria:
inclusion criteria: * acute myocardial infarction and electrocardiographic evidence of st elevation * no clinical evidence of congestive heart failure * all patients must undergo successful percutaneous coronary intervention for thrombolysis in myocardial infarction (timi) 0 or 1 coronary flow with resulting timi 2 or 3 flow * greater than 18 years of age * signed institutional review board (irb) approved informed consent exclusion criteria: * prior myocardial infarction * requirement for urgent cardiac surgery * previous coronary artery bypass graft (cabg) or primary coronary intervention (pci) * left bundle branch block * heart block that is expected to require a temporary pacemaker for greater than 72 hours * prior use of thrombolytic therapy for the current event * unable to tolerate magnetic resonance imaging or unable to tolerate gadolinium contrast media, including patients with a calculated creatinine clearance less than 60 ml/min/1.73m² body surface area (bsa) * active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation, or hemorrhagic stroke within the 6 weeks prior * neutropenia (wbc \<2000 (mm)³), anemia (hct \<30%, thrombocytopenia (thrombocytes \<50,000 (mm)³). it is not necessary to confirm blood counts prior to start of study drug in the absence of clinical suspicion. * known or suspected aortic dissection. * prior history of pulmonary disease requiring chronic oxygen therapy. * pregnancy, lactating, and women of childbearing potential. * medical problem likely to preclude completion of the study. * use of investigational drugs or device within the 30 days prior to enrollment

Keywords: inot44 nomi
an e-health letter intervention for caregivers

Conditions: Caregivers; Acquired Brain Injury

Summary: the purpose of the present study is to conduct a two-arm randomized control trial (rct) comparing individuals receiving the 90second caregiver health letter, with a usual care (routine care received by caregivers) control group. the goals of the present study are: * to evaluate the effectiveness of the 90second caregiver health letter in improving caregiver's self-efficacy (primary outcome), savouring, and quality of life (secondary outcomes). * to evaluate the effectiveness of the 90second caregiver health letter in reducing caregiver's psychological strain and caregiver burden (secondary outcomes). * to examine the impact of levels of engagement with the 90second caregiver health letter on primary and secondary outcomes. * to assess the usability of the 90second caregiver health letter, as it relates to the relevance of topic, user friendliness, and appropriateness of the readability levels. * to evaluate psychometric properties of self-constructed measures in 90second newsletter.

the present study will examine the effectiveness of the 90second caregiver health letter in increasing self-efficacy in a sample of informal caregivers of abi survivors in nova scotia. participants in this study will be recruited from the caring forward trials within cohort study (reb#1025253). the study is funded by the nova scotia department of health and wellness.

Eligibility criteria:
inclusion criteria: * participant is currently enrolled in the caring forward trials within cohort study (reb#1025253) * participant has agreed to be contacted for future studies by dr. mcgrath's staff * participant has agreed for their data to be used for future studies * participant has mild levels of distress, as indicated by mild scores on the dass-21 and/or the zbi-sf exclusion criteria: * participant is not currently enrolled in the caring forward trials within cohort study (reb#1025253) * participant has not agreed to be contacted for future studies by dr. mcgrath's staff * participant has not agreed for their data to be used in future studies * participant does not report mild levels of distress, as indicated by mild scores on the dass-21 and/or the zbi-sf
cognitive impact in patients with covid-19 infection

Conditions: Cognitive Impairment; COVID-19 Respiratory Infection

Summary: sars-cov-2 (severe acute respiratory syndrome- corona virus - 2) infection reframed medical knowledge in many aspects, yet there is still a lot to be discovered. coronavirus disease 19 (covid-19) can cause neuropsychiatric, psychological and psychosocial impairments. literature regarding cognitive impact of covid-19 is still limited. objective: evaluation of cognitive function, anxiety and depression among patients with coronavirus disease 19.

covid-19 results in a variety of symptoms with multi-organ affection, including fever, cough; grave respiratory symptoms, gastrointestinal manifestations and fatigue. as more is learned, neurological and psychological symptoms appear to manifest in a large subscale of patients. headache, dizziness and even a cerebrovascular event have been reported. anosmia and ageusia reported as early indicators of sars-cov-2 infection, suggesting that early neurological involvement may be relevant. public health emergencies as covid-19 are likely to cause adverse neuropsychiatric impacts. cognitive impairments after sars-cov-2 infection were noticed, covid-19 patients complain of poor concentration, declined memory, and insomnia, as well as anxiety and depression symptoms. the battle against covid-19 is still continuing worldwide. people's adherence to confinement regulations and response to vaccination campaigns is essential, which is largely affected by their knowledge, attitudes, and practices towards covid-19. home isolation and social distancing are also associated with fear, frustrations, uncertainty, anxiety and depressive symptoms. during the acute phase of covid-19 infection, about 36% of cases develop neurological symptoms of which 25% can be attributed to the direct involvement of the central nervous system. patients who show neurological symptoms included cases with or without pre-existing neurological disorders. while on intensive care units, patients showed agitation, confusion, and corticospinal tract signs such as enhanced tendon reflexes and clonus. covid-19 can further lead to changes of coagulation and, in particular, to inflammation-induced disseminated intravascular coagulation (dic).

Eligibility criteria:
inclusion criteria: * covid-19 patients diagnosed using real time-polymerase chain reaction to confirm the diagnosis exclusion criteria: * neurological disorders, psychological disorders, dementia, alzheimer's disease, end-organ failure conditions

Keywords: covid-19; cognitive impairment; anxiety; depression
use of surface electromyography biofeedback to improve reaching in children with cerebral palsy

Conditions: Cerebral Palsy; Weakness; Hypertonia

Summary: a newly-developed device for biofeedback of surface emg will be used to either increase or decrease activity in the muscles of children with poor reaching due to cerebral palsy.

children ages newborn to 21 with a diagnosis of arm weakness, hypertonia, or hyperkinesia due to cerebral palsy will be recruited. a muscle that is either over-active or under-active will be selected for each child. the child will be provided with the device to wear for 1 month in order to call attention to the identified muscle. at the beginning and end of the month, reaching will be assessed using three-dimensional kinematic motion capture. the outcome measure will be the speed and curvature of reaching to a target in front of the child.

Eligibility criteria:
inclusion criteria: * weakness, hypertonia, or hyperkinetic disorder affecting one or both arms * reduced speed or quality of reaching exclusion criteria: * any condition that would increase the risk of participation

Keywords: movement disorders childhood
a study to evaluate the effect of cp-690,550 on measures of kidney function in patients with active rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: the purpose of study is to explore the effect of cp-690,550 (tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * the patient must meet the american college of rheumatology (acr) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria. * the patient must have active disease at both screening and predose on day 1 of period 1. * patient must have had an inadequate response to at least one disease-modifying antirheumatic drug (dmard), non-biologic or biologic, due to ineffectiveness or intolerance. exclusion criteria: * pregnant or lactating women * serious medical conditions that would make treatment with cp-690,550 potentially unsafe. * a patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. in particular, a history of allergy to iodine, povidone-iodine, iohexol or other iodinated contrast media.

Keywords: phase 1
dry needling versus percutaneous electrolysis in lumbar multifidus muscles in patients with chronic low back pain.

Conditions: Chronic Low-back Pain

Summary: the aim of this study is to evaluate the reduction of pain of two different treatments in patients with chronic low back pain. patients were divided in two groups. the control group will receive dn treatment, and the experimental group will receive pe, both in the lumbar multifidus muscles.

background: low back pain is one of the most common health problems and a leading cause of disability and absence from work. between 70% and 80% of adults will experience an episode of low back pain and approximately 10.0% of them will become chronic. this has a direct impact on the lumbar stabilizing muscles, giving rise to both structural and functional changes. among the different treatment options, it has been observed that both dry needling (dn) and percutaneous electrolysis (pe) are effective techniques in the management of musculoskeletal pain. aim: to evaluate whether the reduction of pain after the application of pe is superior to the one obtained with dn. methods: a single-blind randomized clinical trial will be conducted in patients with chronic low back pain. the subjects will be divided into two groups. the control group will receive dn treatment, and the experimental group will receive pe, both in the lumbar multifidus muscles. the study variables will be: pain (vas), disability index (oswestry scale), fear of movement (tsk-11sv) and quality of life (sf-12). the measurements will be assessed before, right after and 7 days after a single intervention.

Eligibility criteria:
inclusion criteria: * low back pain ≥ 3 months. * age between 30 and 60 years old. * not being receiving other physical therapy exclusion criteria: * diagnosis of specific lumbar pathology. * history of previous lumbar surgery. * treatment with corticosteroids, anti-inflammatory or antibiotic medication in recent weeks. * oncological processes, febrile symptoms or thrombophlebitis. * skin conditions. * belonephobia. * pacemaker. * pregnancy. * patients with neurological pathology

Keywords: chronic low back pain dry needling percutaneous electrolysis
image driven hepatocellular carcinoma invasiveness evaluation research

Conditions: Hepatocellular Carcinoma Stage III

Summary: hepatocellular carcinoma (hcc) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. currently, there is a lack of non-invasive and simple indicators to predict the prognosis of hcc patients and assist clinical decision-making. the identification of hcc macroscopic or histopathological classification requires large pathological specimens obtained through surgical resection, but only about 20% of patients are eligible for surgical treatment. moreover, most liver cancer diagnoses can be confirmed by imaging examinations without relying on pathological results. for patients who have not undergone surgical resection, the lack of histopathological information during treatment means that there is no basis for judging tumor proliferation and obtaining rich prognostic information. therefore, evaluating the invasion and proliferation ability of hcc based on macroscopic imaging assessment has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. ultrasound and mri are ideal entry points as first-line imaging methods for liver cancer diagnosis. this study aims to evaluate hcc macroscopic or histopathological classification based on multimodal imaging (ultrasound, ct, mri), thereby assessing its invasion and proliferation ability which has important implications for guiding individualized diagnosis and treatment throughout the entire process including surgical strategy guidance, local treatment selection, systemic therapy planning as well as patient follow-up and prognosis evaluation. by analyzing macroscopic image features we aim to explore their cross-scale correlations with hcc macroscopic classification,histopathological classification,and gene molecular typing.


Eligibility criteria:
inclusion criteria: * according to the who classification, the pathological diagnosis is hepatocellular carcinoma. * the initial treatment is curative-intent hepatectomy. * there is no evidence of major vascular/hepatic portal invasion, extrahepatic/lymph node metastasis, or other malignant tumors. * age 18-80 years old. exclusion criteria: · not meeting any one of the inclusion criteria or being unwilling/unable to follow-up.

Keywords: hepatocellular carcinoma prognosis imaging gross classification
minoxidil response testing in males with androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: topical minoxidil is the most common drug used for the treatment of aga in men. while topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low i.e., 30-40% re-grow hair. to observe significant improvement in hair growth, minoxidil is typically used twice daily for a period of at least 16 weeks. due to the significant time commitment and low response rate, a diagnostic test to identify non-responders prior to initiating therapy would be advantageous. minoxidil is converted in the scalp to its active form, minoxidil sulfate, by the sulfotransferase enzyme sult1a1. the enzyme expression is variable among individuals. we have demonstrated in two prior feasibility studies that the sult1a1 enzyme activity in plucked hair follicles correlates with minoxidil response in the treatment of aga and thus can server as a predictive biomarker. consequently, we developed a minoxidil response in-vitro diagnostic kit intended to identify non-responders prior to initiating therapy with 5% topical minoxidil foam. the primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.


Eligibility criteria:
inclusion criteria: * males in overall good health * age: 18 to 49 * diagnosed with male androgenetic alopecia with vertex pattern iiiv, iv, or v on the norwood hamilton scale * willing to have a mini dot tattoo placed in the target area of the scalp * willing to maintain the same hair style, color, shampoo and hair products use, and approximate hair length throughout the study * able to give informed consent * able to comply with the study requirements for 16 consecutive weeks exclusion criteria: * previous adverse event from topical minoxidil treatment * does not use and have not used in the past 6 months anti-androgen therapy such as finasteride * does not use and have not used in the past 6 months minoxidil (topical or oral) * does not take medication known to cause hair thinning such as coumadin and anti-depressants/anti-psychotics * folliculitis * scalp psoriasis * seborrheic dermatitis * inflammatory scalp conditions such as lichen planopilaris

Keywords: alopecia androgenetic alopecia hair loss minoxidil 5% minoxidil foam male pattern hair loss
safety and efficacy study in the treatment of pediatric crohn's disease

Conditions: Crohn Disease

Summary: the purpose of this study is to observe pediatric crohn's disease response to sargramostim in patients with or without steroid therapy at two possible dosage levels.

on 29 may 2009, bayer began transitioning the sponsorship of this trial to genzyme. note: this study was originally posted by sponsor berlex, inc. berlex, inc. was renamed to bayer healthcare, inc.

Eligibility criteria:
inclusion criteria: * have a parent or guardian able to provide written informed consent * be able to provide verbal or written assent depending on age * age 6 to 16 years * have confirmed diagnosis of crohn's disease at study time of study entry based on radiologic, endoscopic, or histologic evaluations * have a pcdai score \>/= 30 points * have a negative serum pregnancy test within 7 days prior to receiving the first dose of sargramostim in female patients who, in the opinion of the investigator, are sexually active and of childbearing potential * be able to self-inject sargramostim or have a designee who can do so * available documentations of weight from 4 to 6 months prior to study entry exclusion criteria: * existing colostomy or ileostomy * immediate need of gi surgery for active gi bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage * gi surgery within 3 month prior to receiving the first dose of sargramostim * symptoms of bowel obstruction or confirmed evidence of a clinically significant stricture within the last 6 month that has not been surgically corrected * use of any of the following medications within 4 weeks prior to receiving the first dose of study drug: 6 mercaptopurine, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide * use of licensed/registered and/or experimental anti-tumor necrosis factor (tnf) therapy such as infliximab or adalimumab within 8 weeks prior to first dose of sargramostim * use of any investigational drug within 4 weeks or 5 half-lives (whichever is greater) prior to receiving the first dose of sargramostim * concurrent use of corticosteroid therapy for crohn's disease, which exceeds a dose of 60 mg/day (or equivalent) of prednisone * inability to comply with protocol requirements or provide informed consent * presence of clinically important comorbid condition(s) unrelated to crohn's disease * prior use of recombinant human gm-csf (sargramostim or molgramostim) or granulocyte colony-stimulating factor (g-csf; filgrastim or pegfilgrastim) * current use of nutritional therapy (i.e., tube feeding or elemental/polymeric diet) which provides \> 50% of daily caloric intake

Keywords: crohn disease
effects of esketamine on acute abdominal pain after tace in patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Transcatheter Arterial Chemoembolization; Pain

Summary: pain is the main complication after tace(transcatheter arterial chemoembolization) for hepatocellular carcinoma, and its pathogenesis is not clear.the pain may be related to partial liver tissue swelling after blocking the tumor blood supply artery embolization agent, transient hepatic swelling causing tension or strain on the liver capsule, and chemical irritation by the anticancer drug-lipiodol mixture,the inadvertent embolization of normal organs and individual sensitivity to pain. ketamine produces anesthetic and analgesic effects mainly by inhibiting nmda receptor(n-methyl-d-aspartic acid receptor), and previous studies have shown that low concentrations of ketamine have obvious analgesic effects. not only that, ketamine also produces analgesic effects by inhibiting opioid receptors via g-protein coupling. in addition, ketamine can bind to monoaminergic receptors in the central and peripheral nervous system, showing an anticholinergic effect and producing an antispasmodic effect. ketamine also inhibits inflammatory pain by reducing nitric oxide production by inhibiting nitric oxide synthase. esketamine is about three to four times more potent than ketamine. therefore,esketamine requires a lower dose, about half the dose of ketamine, to produce anesthetic and analgesic effects, with fewer side effects.


Eligibility criteria:
inclusion criteria: * age 18 to 80 * participate in this study and sign informed consent * voluntarily receive preoperative intravenous analgesia * patients receiving tace treatment * hcc (hepatocellular carcinoma)patients with primary liver cancer bclc(barcelona clinic liver cancer) stage a-c, liver function a-b exclusion criteria: * patients who were unable to cooperate or refused to participate in the trial * pregnant women * patients with or having a history of serious mental disorders * patients with poorly controlled or untreated hypertension (arterial hypertension, resting systolic / diastolic blood pressure more than 180/100mg) * patients with unstable angina pectoris or myocardial infarction within 6 months or congestive heart failure * patients with intracranial hypertension or glaucoma * patients with hyperthyroidism without treatment or insufficient treatment * patients with severe respiratory dysfunction * allergy or existing contraindication to chemotherapeutic drugs, opioids or ketamine drugs